Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose aflibercept vs standard-dose aflibercept in diabetic macular edema
2019-003643-30Phase 2Unknown
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary: Change from baseline in best corrected visual acuity (BCVA) at week 48. Status: unknown.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2019-003643-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003643-30.